Sanwa Kagaku Obtains Additional Approval For Miglitol
This article was originally published in PharmAsia News
Sanwa Kagaku announced the company has obtained an additional indication for diabetic drug Seibule (miglitol), to be used in combination with insulin to lower glucose levels for patients who are less responsive to insulin alone. The company estimates the new addition will increase the drug's sales by 38 percent to ¥18 billion by March 2010, compared to estimated sales for March 2009. Miglitol inhibits glycoside hydrolase enzymes called alpha-glucosidases. (Click here for more - Japanese language
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.